Showing 641 - 660 results of 719 for search '"Houston"', query time: 0.05s Refine Results
  1. 641
  2. 642
  3. 643
  4. 644
  5. 645
  6. 646
  7. 647
  8. 648
  9. 649
  10. 650

    Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States by Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO

    Published 2025-02-01
    “…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email rfinn@mednet.ucla.eduIntroduction: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
    Get full text
    Article
  11. 651
  12. 652
  13. 653
  14. 654
  15. 655
  16. 656
  17. 657
  18. 658
  19. 659
  20. 660